Lia D Delaney1, Vidhya Gunaseelan2, Heidi Rieck2, James Michael Dupree3, Brian R Hallstrom4, Jennifer F Waljee5. 1. University of Michigan Medical School, Ann Arbor, MI. 2. Department of Surgery, University of Michigan, Ann Arbor MI; Michigan Opioid Prescribing Engagement Network, Ann Arbor, MI. 3. Department of Urology, University of Michigan, Ann Arbor, MI. 4. Department of Orthopedic Surgery, University of Michigan, Ann Arbor, MI. 5. Department of Surgery, University of Michigan, Ann Arbor MI; Michigan Opioid Prescribing Engagement Network, Ann Arbor, MI; Michigan Surgical Quality Collaborative, Ann Arbor, MI.
Abstract
BACKGROUND: The association between surgeon prescribing practices and new persistent postoperative opioid use is not well understood. We examined the association between surgeon prescribing and new persistent use among total hip arthroplasty (THA) patients. METHODS: A retrospective analysis of Medicare claims in Michigan was performed. The study cohort consisted of orthopedic surgeons performing THAs from 2013 to 2016 and their opioid-naïve patients, aged >65 years. High-risk prescribing included high daily doses, overlapping benzodiazepine prescriptions, concurrent opioid prescriptions, prescriptions from multiple providers, or long-acting opioid prescriptions. The occurrence of a preoperative prescription, initial prescription size, and 30-day prescription dosage were examined as individual exposures. Surgeons were categorized into quartiles by prescribing practices, and multilevel hierarchical logistic regression was used to examine associations with postoperative new persistent opioid use. RESULTS: Surgeons exhibited high-risk prescribing for 66% of encounters. Patients of surgeons with the highest rates of high-risk prescribing were more likely to develop persistent use compared with patients of surgeons with the lowest rates (adjusted rates: 9.7% vs 4.6%, P = .011). Patients of surgeons with initial prescription sizes in the "high" (third) quartile (adjusted odds ratio, 2.91; 95% confidence interval, 1.53-5.51), and of surgeons in the "highest" (fourth) quartile of 30-day prescription dosage (adjusted odds ratio, 1.93; 95% confidence interval, 1.03-3.61), were more likely to develop persistent opioid use compared with patients of surgeons with low initial and 30-day prescription sizes, respectively. CONCLUSION: The development of persistent opioid use after surgery is multifactorial, and surgeon prescribing patterns play an important role. Reducing prescribing and encouraging opioid alternatives could minimize postoperative persistent opioid use.
BACKGROUND: The association between surgeon prescribing practices and new persistent postoperative opioid use is not well understood. We examined the association between surgeon prescribing and new persistent use among total hip arthroplasty (THA) patients. METHODS: A retrospective analysis of Medicare claims in Michigan was performed. The study cohort consisted of orthopedic surgeons performing THAs from 2013 to 2016 and their opioid-naïve patients, aged >65 years. High-risk prescribing included high daily doses, overlapping benzodiazepine prescriptions, concurrent opioid prescriptions, prescriptions from multiple providers, or long-acting opioid prescriptions. The occurrence of a preoperative prescription, initial prescription size, and 30-day prescription dosage were examined as individual exposures. Surgeons were categorized into quartiles by prescribing practices, and multilevel hierarchical logistic regression was used to examine associations with postoperative new persistent opioid use. RESULTS: Surgeons exhibited high-risk prescribing for 66% of encounters. Patients of surgeons with the highest rates of high-risk prescribing were more likely to develop persistent use compared with patients of surgeons with the lowest rates (adjusted rates: 9.7% vs 4.6%, P = .011). Patients of surgeons with initial prescription sizes in the "high" (third) quartile (adjusted odds ratio, 2.91; 95% confidence interval, 1.53-5.51), and of surgeons in the "highest" (fourth) quartile of 30-day prescription dosage (adjusted odds ratio, 1.93; 95% confidence interval, 1.03-3.61), were more likely to develop persistent opioid use compared with patients of surgeons with low initial and 30-day prescription sizes, respectively. CONCLUSION: The development of persistent opioid use after surgery is multifactorial, and surgeon prescribing patterns play an important role. Reducing prescribing and encouraging opioid alternatives could minimize postoperative persistent opioid use.
Authors: Chad M Brummett; Jennifer F Waljee; Jenna Goesling; Stephanie Moser; Paul Lin; Michael J Englesbe; Amy S B Bohnert; Sachin Kheterpal; Brahmajee K Nallamothu Journal: JAMA Surg Date: 2017-06-21 Impact factor: 14.766
Authors: Roneet Lev; Oren Lee; Sean Petro; Jonathan Lucas; Edward M Castillo; Gary M Vilke; Christopher J Coyne Journal: Am J Emerg Med Date: 2015-09-08 Impact factor: 2.469
Authors: Cornelius A Thiels; Stephanie S Anderson; Daniel S Ubl; Kristine T Hanson; Whitney J Bergquist; Richard J Gray; Halena M Gazelka; Robert R Cima; Elizabeth B Habermann Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: Kevin Berardino; Austin H Carroll; Daniel Popovsky; Robert Ricotti; Matthew D Civilette; William F Sherman; Alan D Kaye Journal: Orthop Rev (Pavia) Date: 2022-05-31
Authors: Shay N Nguyen; Afton L Hassett; Hsou-Mei Hu; Chad M Brummett; Mark C Bicket; Noelle E Carlozzi; Jennifer F Waljee Journal: Reg Anesth Pain Med Date: 2022-08-16 Impact factor: 5.564